GENOME-WIDE METHYLOME ANALYSIS USING METHYLCAP-SEQ UNCOVERS NOVEL METHYLATED MARKERS FOR CANINE LYMPHOMA CELL LINE CLBL-1

The most common type of tumor occurring in canine is the lymphomas. Epigenetic factors like DNA methylation is one of the important factors for causing cancer in canine. Cytology-based screening methods, such as fine needle aspiration (FNA) or immunocytochemistry (ICC), for canine lymphomas lack sensitivity. Despite an improvement in the detection of canine lymphomas by the DNA methylation analysis of lymph scrapings, only few methylation markers have been described. Even though technique like Digital Restriction Enzyme Analysis of Methylation (DREAM) can analyze the methylation profile of canine lymphoma cell line CLBL-1 at very low experimental cost without specific antibodies, the sensitivity and accuracy remain low in comparison to MethylCap-seq. In this study, a methylated DNA fragment of CLBL-1 was successfully captured by a specific protein for MethylCap-seq, and the methylation map of CLBL-1 was reconstructed by high throughput sequencing. For the first time, the genomic methylation region of canine CLBL-1 was analyzed. Using CLBL-1, we aimed to identify novel methylated markers for monitoring canine lymphomas. With the aid of methylation maps, several researchers have attempted to explore the relationship between DNA methylation and specific cancers. Additionally, the discovery of important biomarkers can predict or observe the course of canine cancer. Finally, the proposed advanced methylation information is likely to be suitable as a useful reference for clinical application of canine lymphoma research.

[1]  J. Jelinek,et al.  Dynamic changes in DNA methylation patterns in canine lymphoma cell lines demonstrated by genome-wide quantitative DNA methylation analysis. , 2018, Veterinary journal.

[2]  M. Farrant,et al.  An Essential Role for the Tetraspanin LHFPL4 in the Cell-Type-Specific Targeting and Clustering of Synaptic GABAA Receptors , 2017, Cell reports.

[3]  B. Di Camillo,et al.  DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma , 2017, Scientific Reports.

[4]  Daniel M. Rotroff,et al.  Comprehensive genomic characterization of five canine lymphoid tumor cell lines , 2016, BMC Veterinary Research.

[5]  M. Zandvliet.  Canine lymphoma: a review , 2016, The Veterinary quarterly.

[6]  Xiaohan Liu,et al.  Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization , 2016, Oncoimmunology.

[7]  H. Tsujimoto,et al.  Hypermethylation of the death-associated protein kinase CpG island in canine B-cell lymphoid tumors. , 2014, Veterinary immunology and immunopathology.

[8]  Jinfeng Sun,et al.  High-frequency aberrantly methylated targets in pancreatic adenocarcinoma identified via global DNA methylation analysis using methylCap-seq , 2014, Clinical Epigenetics.

[9]  B. Sander,et al.  Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features , 2014, Oncoscience.

[10]  H. Tsujimoto,et al.  Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma. , 2014, American journal of veterinary research.

[11]  H. Tsujimoto,et al.  Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells. , 2014, Research in veterinary science.

[12]  L. Bargelloni,et al.  Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma , 2014, PloS one.

[13]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[14]  Rasiah Loganantharaj,et al.  PAVIS: a tool for Peak Annotation and Visualization , 2013, Bioinform..

[15]  T. Clozel,et al.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.

[16]  B. Bay,et al.  Ablation of Dihydroceramide Desaturase 1, a Therapeutic Target for the Treatment of Metabolic Diseases, Simultaneously Stimulates Anabolic and Catabolic Signaling , 2013, Molecular and Cellular Biology.

[17]  H. Earp,et al.  Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia , 2013, Oncogene.

[18]  Stefano Comazzi,et al.  The dog as a possible animal model for human non‐Hodgkin lymphoma: a review , 2013, Hematological oncology.

[19]  J. Liao,et al.  Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. , 2013, Blood.

[20]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[21]  J. Sander,et al.  Cancer risk in people with epilepsy using valproate‐sodium , 2012, Acta neurologica Scandinavica.

[22]  Chien-Hsing Lee,et al.  Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma , 2012, Annals of Surgical Oncology.

[23]  D. Coppola,et al.  Down-Regulation of Bax-Interacting Factor 1 in Human Pancreatic Ductal Adenocarcinoma , 2011, Pancreas.

[24]  Chhandak Basu,et al.  Real‐time PCR (qPCR) primer design using free online software , 2011, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[25]  Douglas B. Evans,et al.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma , 2011, Cancer.

[26]  Jingde Zhu,et al.  Whole-genome DNA methylation profiling using MethylCap-seq. , 2010, Methods.

[27]  W. Gerner,et al.  Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. , 2010, Leukemia research.

[28]  Hanna Göransson,et al.  Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. , 2010, Blood.

[29]  Y. Takahashi,et al.  Bif-1/Endophilin B1: a candidate for crescent driving force in autophagy , 2009, Cell Death and Differentiation.

[30]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[31]  T. Yeatman,et al.  Down‐regulation of Bax‐interacting factor‐1 in colorectal adenocarcinoma , 2008, Cancer.

[32]  N. Yoo,et al.  Decreased expression of Bax‐interacting factor‐1 (Bif‐1) in invasive urinary bladder and gallbladder cancers , 2008, Pathology.

[33]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[34]  Vladimir Benes,et al.  Transient cyclical methylation of promoter DNA , 2008, Nature.

[35]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[36]  J. Thierry-Mieg,et al.  AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.

[37]  Yan Yan,et al.  Activation of transcriptional activities of AP-1 and SRE by a new zinc-finger protein ZNF641. , 2006, Biochemical and biophysical research communications.

[38]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[39]  R. Kurten,et al.  The product of the MLD gene is a member of the membrane fatty acid desaturase family: overexpression of MLD inhibits EGF receptor biosynthesis. , 1997, Biochemistry.

[40]  T. Nakano,et al.  Roles of γ‐carboxylation and a sex hormone‐binding globulin‐like domain in receptor‐binding and in biological activities of Gas6 , 1997, FEBS letters.